Global Antibacterial Drugs Market – Treatment for Infectious Disease
Antibacterial drugs play a major role in advanced healthcare, as they are majorly used in treatment and prevention of infectious diseases. Antibacterial drugs act by destroying or inhibiting microbial growth.
The global antibacterial drugs market size was valued at US$ 43,791.2 million in 2017, and is expected to exhibit a CAGR of 1.4% over the forecast period (2018 – 2026).
Figure 1. Global Antibacterial Drugs Market Value (US$ Mn), by Region, 2017
Source: Coherent Market Insights Analysis
Increasing incidences of infectious diseases is expected to propel growth of the antibacterial drugs market
Antibacterial drugs are used in treatment of infection caused by various bacteria such as Escherichia coli, Klebsiella pneumonia, and others. Moreover, increasing incidences of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, HIV/AIDS and others is expected to drive the market growth. According to the World Health Organization (WHO) November 2018 factsheet, an estimated 219 million people were diagnosed by malaria in 2017, in 19 countries.
Moreover, initiatives by government concerned to antibacterial resistance is expected to propel market growth over the forecast period. For instance, in May 2018, the UK government announced fund of US$ 34 million to fight against antimicrobial resistance (AMR). This funding will be distributed to the 4 projects such as Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator of US$ 23 million, Global Antibiotic Research and Development Partnership invested US$ 1 million, and US$ 5 million for two project such as bilateral partnership with Argentina and Foundation for Innovative New Diagnostics.
Figure 2. Global Antibacterial Drugs Market Share (%), by Drug Class, 2018 and 2026
Source: Coherent Market Insights Analysis
Increasing population and high incidences of infectious diseases in North America are expected to bolster the market growth
North America holds dominant position in the global antibacterial drugs market, owing to rising population base susceptible to infectious diseases and higher incidences of infectious diseases such as tuberculosis and others. According to the Centers for Disease Control and Prevention (CDC), in 2017, an estimated 9,105 patients were diagnosed with tuberculosis in the U.S.
Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to treat patients diagnosed with infectious diseases. For instance, in February 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Egaten, used for the treatment of Fascioliasis caused by Fasciola hepatica infection.
Major players operating in the global antibacterial drugs market include Novartis AG, Allergan, Bristol Myers Squibb Company, AstraZeneca, Johnson and Johnson, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi SA, Bayer AG, and Pfizer Inc.
Antibacterial drugs are used in treatment or prohibition of bacterial infections caused due to various factors such as climatic changes, unhygienic lifestyle specially in emerging economies and others. Major challenge associated with antibacterial drugs is resistance of bacteria towards it. Significant studies are carried out to develop new antibacterial drugs to combat these problems.
Increasing prevalence of infectious diseases is a major factor driving antibacterial drugs market growth. According to World Health Organization (WHO), September 2018, annually around 11 million to 21 million cases of typhoid fever are reported worldwide. Moreover, growing geriatric population susceptible to high risk of bacterial infection, majorly caused due to age related changes in immunology is expected to boost the market growth. The Current Opinion in Microbiology Journal 2016, stated Lower respiratory tract infection (Pneumonia), as the most common cause of infection disease in older patients in the U.S. and estimated it as 6 leading cause of death in the U.S.
However, price control of antibacterial drugs, genetic mutation in aging population, and decrease in financial incentives has distracted the focus of pharmaceutical companies from research and development of antibacterial drugs. In September 2016, AstraZeneca announced an agreement with Pfizer to sell the development and commercialization rights to its late-stage small molecule antibiotics business as AstaZeneca does not find antibiotic research as major area for development in their business
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 25 market data tables and 27 figures on "Antibacterial Drugs Market - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.